Experimental cocktail takes on tough pancreatic cancer
NCT ID NCT06076837
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding two immunotherapy drugs (botensilimab and balstilimab) to a strong chemotherapy mix plus two oral medications (chloroquine and celecoxib) can help people with metastatic pancreatic cancer that hasn't been treated yet. The study involves 6 participants and focuses on finding the safest dose and checking for side effects. It is not a cure, but aims to better control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trials Nurse Navigator
Scottsdale, Arizona, 85258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- Smart drug delivers chemo directly to pancreatic cancer cells